Ispitivanja za praćenje

Klinička ispitivanja peptida iz kataloga koja su u toku ili su nedavno završena. Faza, status, broj učesnika i datumi preuzeti su s ClinicalTrials.gov i mijenjaju se kako sponzori ažuriraju registar.

Primarni završetak je trenutak kada je kod posljednjeg učesnika izmjeren glavni ishod; rezultati obično slijede mjesecima kasnije. Podaci iz registra provjereni 2. okt 2026..

Očekuju se rezultati

  1. Faza 3Aktivno, ne uključuje nove učesnike

    STEP Young(otvara izvor u novoj kartici)

    A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

    Primarni završetak: 15. okt 2025.210 učesnikaSponzor: Novo Nordisk A/SNCT05726227

  2. Faza 3Aktivno, ne uključuje nove učesnike

    Afamelanotide plus NB-UVB in vitiligo(otvara izvor u novoj kartici)

    A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

    Očekivani primarni završetak: decembar 2025.200 učesnikaSponzor: Clinuvel, Inc.NCT06109649

  3. Faza 2, Faza 3Aktivno, ne uključuje nove učesnike

    Intranasal oxytocin for chronic pain(otvara izvor u novoj kartici)

    Evaluating the Efficacy of Intranasal Oxytocin on Chronic Pain

    Očekivani primarni završetak: 31. mar 2026.336 učesnikaSponzor: Memorial University of NewfoundlandNCT04903002

  4. Faza 2Uključuje učesnike

    Mazdutide in MASH(otvara izvor u novoj kartici)

    A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    Očekivani primarni završetak: 30. apr 2026.165 učesnikaSponzor: Innovent Biologics (Suzhou) Co. Ltd.NCT06937749

  5. Faza 2Uključuje učesnike

    Vosoritide in idiopathic short stature(otvara izvor u novoj kartici)

    A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

    Očekivani primarni završetak: juni 2026.100 učesnikaSponzor: BioMarin PharmaceuticalNCT06382155

  6. Faza 3Aktivno, ne uključuje nove učesnike

    SURMOUNT-ADOLESCENTS(otvara izvor u novoj kartici)

    A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

    Primarni završetak: 2. jun 2026.160 učesnikaSponzor: Eli Lilly and CompanyNCT06075667

  7. Faza 3Aktivno, ne uključuje nove učesnike

    CANOPY-HCH-3(otvara izvor u novoj kartici)

    Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

    Očekivani primarni završetak: 1. aug 2026.80 učesnikaSponzor: BioMarin PharmaceuticalNCT06455059

  8. Faza 3Uključuje učesnike

    Mazdutide in hypertension(otvara izvor u novoj kartici)

    Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

    Očekivani primarni završetak: 1. aug 2026.336 učesnikaSponzor: Innovent Biologics (Suzhou) Co. Ltd.NCT07469800

  9. Faza 3Aktivno, ne uključuje nove učesnike

    TRANSCEND-T2D-2(otvara izvor u novoj kartici)

    Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

    Primarni završetak: 27. aug 2026.1.250 učesnikaSponzor: Eli Lilly and CompanyNCT06260722

  10. Faza 2Aktivno, ne uključuje nove učesnike

    INFLAM MOTION(otvara izvor u novoj kartici)

    A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

    Primarni završetak: 31. aug 2026.129 učesnikaSponzor: 4Moving BiotechNCT07225829

  11. Faza 2Aktivno, ne uključuje nove učesnike

    Mazdutide in heart failure(otvara izvor u novoj kartici)

    A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity

    Očekivani primarni završetak: 24. sep 2026.141 učesnikSponzor: Innovent Biologics (Suzhou) Co. Ltd.NCT06862908

  12. Faza 2Aktivno, ne uključuje nove učesnike

    Linaclotide in colorectal neoplasia(otvara izvor u novoj kartici)

    Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

    Očekivani primarni završetak: 30. sep 2026.150 učesnikaSponzor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityNCT03796884

  13. Faza 2Uključuje učesnike

    OxyTUTION(otvara izvor u novoj kartici)

    Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus

    Očekivani primarni završetak: oktobar 2026.112 učesnikaSponzor: University Hospital, Basel, SwitzerlandNCT06036004

  14. Faza 2Još ne uključuje učesnike

    Sublingual oxytocin for PPH(otvara izvor u novoj kartici)

    Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage

    Očekivani primarni završetak: 30. okt 2026.330 učesnikaSponzor: Insud PharmaNCT06968481

  15. Faza 3Aktivno, ne uključuje nove učesnike

    SURPASS-T1D-1(otvara izvor u novoj kartici)

    A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

    Očekivani primarni završetak: novembar 2026.905 učesnikaSponzor: Eli Lilly and CompanyNCT06914895

  16. Faza 3Aktivno, ne uključuje nove učesnike

    TRIUMPH-5(otvara izvor u novoj kartici)

    A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

    Očekivani primarni završetak: novembar 2026.800 učesnikaSponzor: Eli Lilly and CompanyNCT06662383

  17. Faza 3Aktivno, ne uključuje nove učesnike

    OVELIA(otvara izvor u novoj kartici)

    Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

    Očekivani primarni završetak: 30. nov 2026.250 učesnikaSponzor: Tolmar Inc.NCT04906395

  18. Faza 2Aktivno, ne uključuje nove učesnike

    LOCITT(otvara izvor u novoj kartici)

    The Long COVID Treatment Trial

    Očekivani primarni završetak: decembar 2026.1.000 učesnikaSponzor: Scripps Translational Science InstituteNCT07128082

  19. Faza 3Aktivno, ne uključuje nove učesnike

    GLORY-3(otvara izvor u novoj kartici)

    A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

    Očekivani primarni završetak: 31. dec 2026.479 učesnikaSponzor: Innovent Biologics (Suzhou) Co. Ltd.NCT06884293

  20. Faza 2Aktivno, ne uključuje nove učesnike

    FAST-Healing(otvara izvor u novoj kartici)

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

    Očekivani primarni završetak: februar 2027.96 učesnikaSponzor: Hospital for Special Surgery, New YorkNCT03841058

  21. Faza 2, Faza 3Uključuje učesnike

    Thy-α1 for RIF(otvara izvor u novoj kartici)

    Thymosin-α1 for Recurrent Implantation Failure

    Očekivani primarni završetak: februar 2027.136 učesnikaSponzor: Fakih IVF Fertility CenterNCT07675980

  22. Faza 3Aktivno, ne uključuje nove učesnike

    Teduglutide in Chinese adults with SBS(otvara izvor u novoj kartici)

    A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

    Očekivani primarni završetak: 10. feb 2027.13 učesnikaSponzor: TakedaNCT06973304

  23. Faza 2Uključuje učesnike

    INHALE-1st(otvara izvor u novoj kartici)

    INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

    Očekivani primarni završetak: mart 2027.100 učesnikaSponzor: Mannkind CorporationNCT07224321

  24. Faza 3Uključuje učesnike

    Congenital hypothalamic obesity(otvara izvor u novoj kartici)

    A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

    Očekivani primarni završetak: 13. mar 2027.39 učesnikaSponzor: Rhythm Pharmaceuticals, Inc.NCT06760546

  25. Faza 3Uključuje učesnike

    Liraglutide for delirium after surgery(otvara izvor u novoj kartici)

    Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

    Očekivani primarni završetak: 31. mar 2027.260 učesnikaSponzor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06361238

  26. Faza 3Uključuje učesnike

    Thymosin alpha-1 in colorectal cancer(otvara izvor u novoj kartici)

    Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

    Očekivani primarni završetak: 31. mar 2027.2.500 učesnikaSponzor: Fudan UniversityNCT05086614

  27. Faza 3Još ne uključuje učesnike

    Oral insulin ORMD-0801 in T2D(otvara izvor u novoj kartici)

    A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

    Očekivani primarni završetak: 25. apr 2027.300 učesnikaSponzor: Oramed, Ltd.NCT06731075

  28. Faza 3Još ne uključuje učesnike

    Abaloparatide vs teriparatide in China(otvara izvor u novoj kartici)

    To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

    Očekivani primarni završetak: maj 2027.282 učesnikaSponzor: Qilu Pharmaceutical Co., Ltd.NCT06898060

  29. Faza 3Uključuje učesnike

    GLORY-OSA(otvara izvor u novoj kartici)

    A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

    Očekivani primarni završetak: 7. maj 2027.260 učesnikaSponzor: Innovent Biologics (Suzhou) Co. Ltd.NCT06931028

  30. Faza 3Aktivno, ne uključuje nove učesnike

    RENEW 1(otvara izvor u novoj kartici)

    Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

    Očekivani primarni završetak: 11. maj 2027.300 učesnikaSponzor: Novo Nordisk A/SNCT07220642

  31. Faza 3Aktivno, ne uključuje nove učesnike

    RENEW 2(otvara izvor u novoj kartici)

    Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

    Očekivani primarni završetak: 12. maj 2027.330 učesnikaSponzor: Novo Nordisk A/SNCT07220759

  32. Faza 3Aktivno, ne uključuje nove učesnike

    ReNEW(otvara izvor u novoj kartici)

    ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

    Očekivani primarni završetak: august 2027.313 učesnikaSponzor: Stealth BioTherapeutics Inc.NCT06373731

  33. Faza 3Aktivno, ne uključuje nove učesnike

    Adjuvant leuprorelin after prostatectomy(otvara izvor u novoj kartici)

    Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

    Očekivani primarni završetak: septembar 2027.700 učesnikaSponzor: UNICANCERNCT01442246

  34. Faza 3Uključuje učesnike

    OPIC(otvara izvor u novoj kartici)

    Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening

    Očekivani primarni završetak: septembar 2027.1.494 učesnikaSponzor: University Hospital, ToursNCT04949633

  35. Faza 3Aktivno, ne uključuje nove učesnike

    TRIUMPH-7(otvara izvor u novoj kartici)

    A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

    Očekivani primarni završetak: septembar 2027.586 učesnikaSponzor: Eli Lilly and CompanyNCT07035093

  36. Faza 3Aktivno, ne uključuje nove učesnike

    REDEFINE 3(otvara izvor u novoj kartici)

    REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

    Očekivani primarni završetak: 1. sep 2027.7.101 učesnikSponzor: Novo Nordisk A/SNCT05669755

  37. Faza 2Uključuje učesnike

    TAB(otvara izvor u novoj kartici)

    Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Očekivani primarni završetak: 30. sep 2027.310 učesnikaSponzor: T. John Winhusen, PhDNCT06651177

  38. Faza 3Aktivno, ne uključuje nove učesnike

    SURMOUNT-MMO(otvara izvor u novoj kartici)

    A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

    Očekivani primarni završetak: oktobar 2027.15.374 učesnikaSponzor: Eli Lilly and CompanyNCT05556512

  39. Faza 3Aktivno, ne uključuje nove učesnike

    ADOPT(otvara izvor u novoj kartici)

    Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

    Očekivani primarni završetak: 21. okt 2027.280 učesnikaSponzor: University Medical Center GroningenNCT04302454

  40. Faza 3Uključuje učesnike

    GLORY-YOUNG(otvara izvor u novoj kartici)

    A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

    Očekivani primarni završetak: 31. okt 2027.180 učesnikaSponzor: Innovent Biologics (Suzhou) Co. Ltd.NCT07255209

  41. Faza 3Aktivno, ne uključuje nove učesnike

    FOCUS(otvara izvor u novoj kartici)

    A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

    Očekivani primarni završetak: 7. nov 2027.1.500 učesnikaSponzor: Novo Nordisk A/SNCT03811561

  42. Faza 2Još ne uključuje učesnike

    ARTIST-CKD(otvara izvor u novoj kartici)

    Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

    Očekivani primarni završetak: 30. nov 2027.120 učesnikaSponzor: University Medical Center GroningenNCT07206290

  43. Faza 3Uključuje učesnike

    AWARD-PEDS PLUS(otvara izvor u novoj kartici)

    A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

    Očekivani primarni završetak: decembar 2027.55 učesnikaSponzor: Eli Lilly and CompanyNCT06739122

  44. Faza 3Uključuje učesnike

    Survodutide in type 2 diabetes(otvara izvor u novoj kartici)

    A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Očekivani primarni završetak: 17. jan 2028.600 učesnikaSponzor: Boehringer IngelheimNCT07754461

  45. Faza 2Uključuje učesnike

    TRIUMPH (tesamorelin)(otvara izvor u novoj kartici)

    Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

    Očekivani primarni završetak: 16. jun 2028.100 učesnikaSponzor: Massachusetts General HospitalNCT06554717

  46. Faza 3Uključuje učesnike

    AMAZE 9(otvara izvor u novoj kartici)

    AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

    Očekivani primarni završetak: 27. jun 2028.950 učesnikaSponzor: Novo Nordisk A/SNCT07720271

  47. Faza 2Uključuje učesnike

    Vosoritide in infant hypochondroplasia(otvara izvor u novoj kartici)

    A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

    Očekivani primarni završetak: 30. jun 2028.60 učesnikaSponzor: BioMarin PharmaceuticalNCT07126262

  48. Faza 3Uključuje učesnike

    AMAZE 3(otvara izvor u novoj kartici)

    AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

    Očekivani primarni završetak: 12. jul 2028.300 učesnikaSponzor: Novo Nordisk A/SNCT07571005

  49. Faza 3Još ne uključuje učesnike

    SYNCHRONIZE-HERA(otvara izvor u novoj kartici)

    SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

    Očekivani primarni završetak: 26. jul 2028.600 učesnikaSponzor: Boehringer IngelheimNCT07850050

  50. Faza 3Uključuje učesnike

    AMBITION 7(otvara izvor u novoj kartici)

    AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

    Očekivani primarni završetak: 31. jul 2028.1.778 učesnikaSponzor: Novo Nordisk A/SNCT07797335

  51. Faza 3Uključuje učesnike

    AMAZE 2(otvara izvor u novoj kartici)

    AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    Očekivani primarni završetak: 7. aug 2028.630 učesnikaSponzor: Novo Nordisk A/SNCT07533175

  52. Faza 3Uključuje učesnike

    AMAZE 5(otvara izvor u novoj kartici)

    A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

    Očekivani primarni završetak: 14. aug 2028.400 učesnikaSponzor: Novo Nordisk A/SNCT07481630

  53. Faza 2Uključuje učesnike

    CBCT-OT RCT(otvara izvor u novoj kartici)

    Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD

    Očekivani primarni završetak: 30. sep 2028.240 učesnikaSponzor: VA Office of Research and DevelopmentNCT06194851

  54. Faza 3Uključuje učesnike

    AMAZE 7(otvara izvor u novoj kartici)

    A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

    Očekivani primarni završetak: 10. okt 2028.650 učesnikaSponzor: Novo Nordisk A/SNCT07668414

  55. Faza 2, Faza 3Uključuje učesnike

    Pulsatile GnRH in Down syndrome(otvara izvor u novoj kartici)

    GnRH Therapy on Cognition in Down Syndrome

    Očekivani primarni završetak: decembar 2028.56 učesnikaSponzor: Nelly PitteloudNCT04390646

  56. Faza 3Još ne uključuje učesnike

    AMAZE 8(otvara izvor u novoj kartici)

    AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    Očekivani primarni završetak: 12. dec 2028.1.000 učesnikaSponzor: Novo Nordisk A/SNCT07400107

Završena ili zaustavljena

  1. Faza 2Završeno

    Thymosin alpha-1 in lung cancer(otvara izvor u novoj kartici)

    The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

    Primarni završetak: 30. jun 2026.114 učesnikaSponzor: Sun Yat-sen UniversityNCT06139419

  2. Faza 3Završeno

    TRIUMPH-2(otvara izvor u novoj kartici)

    A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

    Primarni završetak: 16. jun 2026.1.152 učesnikaSponzor: Eli Lilly and CompanyNCT05929079

  3. Faza 3Završeno

    SYNCHRONIZE-CVOT(otvara izvor u novoj kartici)

    A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

    Primarni završetak: 1. jun 2026.5.531 učesnikSponzor: Boehringer IngelheimNCT06077864

  4. Faza 3Završeno

    TRIUMPH-3(otvara izvor u novoj kartici)

    A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

    Primarni završetak: 16. apr 2026.1.946 učesnikaSponzor: Eli Lilly and CompanyNCT05882045

  5. Faza 2Završeno

    COPE+OT(otvara izvor u novoj kartici)

    Oxytocin to Enhance Integrated Treatment for AUD and PTSD

    Primarni završetak: 13. apr 2026.175 učesnikaSponzor: Medical University of South CarolinaNCT04523922

  6. Faza 3Završeno

    TRIUMPH-1(otvara izvor u novoj kartici)

    A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

    Primarni završetak: 6. apr 2026.2.335 učesnikaSponzor: Eli Lilly and CompanyNCT05929066

  7. Faza 2Završeno

    Mazdutide in alcohol use disorder(otvara izvor u novoj kartici)

    A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

    Primarni završetak: 19. mar 2026.308 učesnikaSponzor: Eli Lilly and CompanyNCT06817356

  8. Faza 3Završeno

    TRANSCEND-T2D-1(otvara izvor u novoj kartici)

    Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

    Primarni završetak: 22. jan 2026.537 učesnikaSponzor: Eli Lilly and CompanyNCT06354660

  9. Faza 3Završeno

    TOGETHER-PsO(otvara izvor u novoj kartici)

    Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

    Primarni završetak: 8. jan 2026.281 učesnikSponzor: Eli Lilly and CompanyNCT06588283

  10. Faza 3Završeno

    EMANATE(otvara izvor u novoj kartici)

    EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

    Primarni završetak: 22. dec 2025.296 učesnikaSponzor: Rhythm Pharmaceuticals, Inc.NCT05093634

  11. Faza 3Završeno

    SYNCHRONIZE-2(otvara izvor u novoj kartici)

    A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

    Primarni završetak: 12. dec 2025.755 učesnikaSponzor: Boehringer IngelheimNCT06066528

  12. Faza 3Završeno

    CagriSema vs tirzepatide in obesity(otvara izvor u novoj kartici)

    A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

    Primarni završetak: 8. dec 2025.809 učesnikaSponzor: Novo Nordisk A/SNCT06131437

  13. Faza 3Završeno

    Leuprolide mesylate in early puberty(otvara izvor u novoj kartici)

    Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

    Primarni završetak: 7. dec 2025.94 učesnikaSponzor: Foresee Pharmaceuticals Co., Ltd.NCT05493709

  14. Faza 3Završeno

    SYNCHRONIZE-1(otvara izvor u novoj kartici)

    A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

    Primarni završetak: 2. dec 2025.726 učesnikaSponzor: Boehringer IngelheimNCT06066515

  15. Faza 3Završeno

    REIMAGINE 2(otvara izvor u novoj kartici)

    A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

    Primarni završetak: 19. nov 2025.2.734 učesnikaSponzor: Novo Nordisk A/SNCT06065540

  16. Faza 3Završeno

    TRIUMPH-4(otvara izvor u novoj kartici)

    A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

    Primarni završetak: 14. nov 2025.445 učesnikaSponzor: Eli Lilly and CompanyNCT05931367

  17. Faza 2Završeno

    Exenatide for smoking cessation(otvara izvor u novoj kartici)

    Exenatide for Smoking Cessation and Prevention of Weight Gain

    Primarni završetak: 7. nov 2025.140 učesnikaSponzor: The University of Texas Health Science Center, HoustonNCT05610800

  18. Faza 3Završeno

    SYNCHRONIZE-MASLD(otvara izvor u novoj kartici)

    A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

    Primarni završetak: 9. okt 2025.218 učesnikaSponzor: Boehringer IngelheimNCT06309992

  19. Faza 2Završeno

    Amycretin in type 2 diabetes(otvara izvor u novoj kartici)

    A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

    Primarni završetak: 1. okt 2025.448 učesnikaSponzor: Novo Nordisk A/SNCT06542874

  20. Faza 3Završeno

    DREAMS-3(otvara izvor u novoj kartici)

    A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

    Primarni završetak: 17. sep 2025.349 učesnikaSponzor: Innovent Biologics (Suzhou) Co. Ltd.NCT06184568

  21. Faza 3Završeno

    EVOKE(otvara izvor u novoj kartici)

    A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

    Primarni završetak: 16. sep 2025.1.840 učesnikaSponzor: Novo Nordisk A/SNCT04777396

  22. Faza 3Završeno

    EVOKE Plus(otvara izvor u novoj kartici)

    A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

    Primarni završetak: 15. sep 2025.1.840 učesnikaSponzor: Novo Nordisk A/SNCT04777409

  23. Faza 3ZavršenoRezultati objavljeni

    Linaclotide in constipation, ages 2 to 5(otvara izvor u novoj kartici)

    A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

    Primarni završetak: 2. sep 2025.123 učesnikaSponzor: AbbVieNCT05652205

  24. Faza 2Završeno

    SEMALCO(otvara izvor u novoj kartici)

    Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

    Primarni završetak: 31. jul 2025.108 učesnikaSponzor: Psychiatric Centre RigshospitaletNCT05895643